- October 25, 2011
Moderator: Jason Kantor, PhD, Managing Director, RBC Capital Markets
Hervé Brailly, PhD, Chief Executive Officer, Innate Pharma SA,
Kevin N. Heller, MD, Director, Immuno-Oncology- Strategic Transactions Group, Bristol-Myers Squibb Company
Carlos Paya, MD, PhD, President & Chief Executive Officer, Immune Design Corp.
Timothy C. Rodell, MD, Chief Executive Officer & President, Globeimmune, Inc
- November 24, 2011
- December 9, 2011
- January 20, 2012
A research lead by Eric Vivier and Sophie Ugolini of the Centre d'Immunologie de Marseille-Luminy (CIML - Inserm/CNRS/Aix Marseille Université) has revealed a new gene that, when mutated, stimulates the immune systems to fight better against tumours and viral infections.